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Background. Due to unacceptably high mortality with pentavalent antimonials, Me ´decins Sans Frontie `res in
2006 began using liposomal amphotericin B (AmBisome) for visceral leishmaniasis (VL) patients in Ethiopia who
were severely ill or positive for human immunodeﬁciency virus (HIV).
Methods. We used clinical data obtained from January 2007 to January 2009 to compare outcomes by HIV
status and VL episode (primary vs relapse) and to identify risk factors for treatment failure among patients treated
with AmBisome monotherapy at a total dose of 30 mg/kg in 6 doses on alternate days, a higher dose than
recommended by the World Health Organization (20 mg/kg).
Results. Among 94 HIV-negative severely ill VL patients, 93% had initial cure and 6% died. Among 195 HIV-
positive patients (116 primary, 79 relapse VL), 60% had initial cure, 7% died, and 32% were parasitological failures.
AmBisome was less effective in the 79 HIV-positive VL relapse patients (38% initial cure, 5% mortality, 56%
parasitological failure) than in the 116 HIV-positive primary VL patients (74% initial cure, 8% mortality, 16%
parasitological failure). Sodium stibogluconate (SSG) rescue treatment increased the overall cure rate among all HIV-
positiveVLpatientsfrom60%to83%,but16%(9of59)ofrescuetreatmentpatientsdied,mainlyduetoSSGtoxicity.
Conclusions. High-dose AmBisome for VL is safe and effective in severely ill HIV-negative patients, and safe
but less effective in HIV-positive patients. Combining AmBisome withanother drug mayenhance its effectiveness in
HIV-positive VL patients. SSG should be avoided for treatment of VL in HIV-positive patients.
Visceral leishmaniasis (VL; ‘‘kala-azar’’) is a systemic
parasitic disease caused by the Leishmania donovani
species complex. Transmission, via sandﬂies, is an-
throponotic. VL is endemic in large areas of East Africa,
including the lowlands between Humera and Metema
in northern Ethiopia. Me ´decins Sans Frontie `res (MSF)
has diagnosed and treated up to 2000 VL patients an-
nually in this area since 1997. The VL-affected pop-
ulation comprises mainly male (.90%) migrant farm
laborers. Many patients present with advanced severe
VL because of difﬁculties in accessing treatment. Pen-
tavalent antimonials (sodium stibogluconate; SSG), the
mainstay of VL treatment in East Africa, remains very
efﬁcacious [1–5], but treatment-associated mortality in
VL patients with human immunodeﬁciency virus (HIV)
infection [3, 4, 6] and immunocompetent patients with
severe VL [7, 8] is unacceptably high.
HIV has expanded into northern Ethiopia via the
migrantruralworkforce.TheHIVcoinfectionrateinVL
patientsrose from 19%in 1999to 34%in 2009[3,4,6,9].
Most studies of HIV/VL coinfection originated pre-
1996 in southern Europe and are not representative of
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 the situation in Ethiopia where the parasite ismore virulent and
different
comorbidities occur [10–13]. HIV/VL coinfection in Africa is
characterized by high parasite load, parasite dissemination to
unusual sites, lower initial and ﬁnal cure rates, greater sus-
ceptibility to pentavalent antimonial drug toxicity, increased
risk of secondary drug resistance, higher rates of death, and
very high rates of relapse [3, 4, 14, 15].
Studies from Europe, India, and Brazil have demonstrated
that liposomal amphotericin B (AmBisome) has high efﬁcacy
and low toxicity in immunocompetent VL patients [16]. It is
also the preferred antileishmanial drug in HIV-positive VL
patients, although the data are more limited and originate
predominantly from Europe. The World Health Organization
(WHO) recommends a total AmBisome dose of 20 mg/kg to
treat immunocompetent children and adults [17], but we re-
ported that 16% (10 of 64) of patients in Sudan did not respond
to treatment at this dose [18]. We attributed this high failure
ratetohighinitialparasiteloadsandimmunosuppressiondueto
underlyingHIV infection and/ortuberculosis, andwe speculated
that higher doses should be used. Total doses of 30–40 mg/kg
were well tolerated in HIV-positive VL patients in Europe [19].
Hence, we introduced AmBisome into MSF programs in
Ethiopia in 2006 as ﬁrst-line treatment for HIV-positive and
severely ill immunocompetent VL patients at a total dose of
30 mg/kg. In this retrospective cohort analysis we assess the
effectivenessof high-dose AmBisomemonotherapyandidentify
risk factors for treatment failure.
METHODS
Study Design and Population
Our study population comprised severely ill and HIV-positive
VL patients diagnosed and treated within an integrated HIV/VL
program at MSF clinics in Humera (western Tigray) and Abduraﬁ
(northern Amhara) in northern Ethiopia from January 2007 to
January 2009. All investigations and treatments for all patients
were free of charge. Our analysis included all patients treated with
AmBisome monotherapy. Patients given AmBisome in combi-
nation with another antileishmanial drug, or who were switched
from SSG to AmBisome due to SSG intolerance, were excluded.
Visceral Leishmaniasis Diagnosis
Diagnosis was according to standard MSF practice [20]. The
WHO case deﬁnition of VL was used as a starting point: history
of fever for .2 weeks, malaria excluded, in combination with
wasting, and either splenomegaly or lymphadenopathy [21].
Patients whose illness met this case deﬁnition, and who had no
previous VL treatment, were diagnosed serologically either by
positive rK39 rapid diagnostic test (DiaMed-IT-Leish, DiaMed
AG) [22]o rb yh i g h - t i t e r( $1:6400) leishmania direct
agglutination test (DAT) (Royal Tropical Institute) [23]. Pa-
tients with an intermediate DAT titer (1:800–1:3200) underwent
splenic or lymph node aspiration, and VL was conﬁrmed par-
asitologically. Patients with suspected VL but a negative rK39
test and low DAT titer (,1:400) were evaluated for alternative
illnesses and retested if their illness persisted. Severely ill patients
with a negative rK39 test were aspirated without delay. Patients
fulﬁlling the case deﬁnition but with previous VL treatment
(suspected VL relapse patients) were treated only if they had
a positive aspirate. A clinical diagnosis of relapse was made if
splenic aspiration was contraindicated due to a barely palpable
spleen, pregnancy, bleeding tendency, severe anemia, jaundice,
or state of collapse.
HIV Testing and Treatment
Patients were offered counseling and testing for HIV immedi-
ately after conﬁrmation of VL diagnosis. Two rapid diagnostic
HIV tests were used in parallel (HIV-Determine, Abbott Diag-
nostics and Unigold, Trinity Biotech) using venous blood [24].
All positive HIV results were conﬁrmed by repeat tests on
a second blood sample. Patients with discordant results were
asked toretest after6 weeks and were considered HIV negative if
test results were again discordant. VL patients coinfected with
HIV were offered follow-up care in our clinic for HIV/AIDS,
including diagnosis and treatment of opportunistic infections,
Pneumocystis jiroveci pneumonia prophylaxis, tuberculosis
treatment, psychosocial support, shelter for homeless patients,
and therapeutic feeding. HIV-positive VL patients were offered
antiretroviral treatment (ART) if they were well motivated for
lifelong ART and had not defaulted from the follow-up clinic.
Assessment of Visceral Leishmaniasis Severity
Severity of VL disease was assessed by a scoring system com-
bining scores for different factors associated with .20% in-
creased risk of death, including general weakness, old age, low
body mass index, and/or low hemoglobin levels [7].
Visceral Leishmaniasis Treatment Regimens
Primary nonsevere VL was treated with SSG (Albert David,
CalcuttaandInternationalDispensaryAssociation)20mg/kg/day
by intramuscular injection for 30 days. Severely ill VL patients,
patients with known intolerance to SSG, patients with VL re-
lapse,andHIV-positiveVLpatientsweretreatedwithAmBisome
(Gilead Sciences) at a total dose of 30 mg/kg, divided into
6 infusions of 5 mg/kg on alternate days. Primary and relapse VL
patients failing AmBisome treatment received rescue treatment
with SSG (20 mg/kg/day) for 30 days and 40 days, respectively.
Visceral Leishmaniasis Treatment Outcomes
In HIV-negative primary VL, initial cure was established clini-
callybyobservingfeverresolution,spleenregression,hemoglobin
increase,andweightgain. Aparasitologicaltestofcurebysplenic
High-Dose AmBisome for Visceral Leishmaniasis in Ethiopia d CID 2011:53 (15 December) d e153
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 aspirate was performed on day 28 in HIV-positive and relapsed
patients or if clinical response to primary VL treatment was
uncertain. If a test-of-cure aspirate could not be done because
of absence of palpable spleen or lymph nodes after treatment,
initial cure was established clinically. Patients were considered
to have failed treatment if they showedparasitological failureafter
AmBisome monotherapy irrespective of clinical response, died
during treatment, defaulted from treatment, or were transferred
to another hospital because of treatment complications.
Data Entry and Statistical Analysis
Data were extracted from medical records and single-entered
into an Excel (Microsoft) spreadsheet. Characteristics of groups
(HIV positive vs HIV negative; primary vs relapse VL) were
compared using Fisher exact test for categorical variables and
Student t test for continuous variables (Epi Info 2002 soft-
ware, revision 2, Centers for Disease Control and Prevention).
Multivariable logistic regression models were used to identify
independent risk factors for parasitological failure (Stata
software version 10, StataCorp).
Ethical Approval
Datawere collectedaspart ofroutine patient care.Noadditional
investigations were performed other than those indicated for
medical management. The study underwent ethical review
according to MSF procedures for routine programmatic
data.
RESULTS
Patients
Between January 2007 and January 2009, 362 patients (277 in
Humera, 85 in Abduraﬁ) were treated with AmBisome (Figure 1).
Forty-nine patients who had started SSG treatment but who
were switched to AmBisome due to SSG toxicity were excluded
from our analysis, as were 24 patients with unknown HIV
status. Of the 289 patients included in our analysis, 94 (32.5%)
tested HIV negative, 195 (67.5%) HIV positive. Of the 94 HIV-
negative patients, 84 (89.4%) were severely ill primary VL patients
and 10 were VL relapse patients. Of the 195 HIV-positive patients,
116 (59.5%) had primary VL and 79 (40.5%) had VL relapse.
In total, 173 (86.5%) primary VL patients were diagnostically
conﬁrmed by serological test (rK39 and/or DAT) and 17 (8.5%)
by splenic aspirate, and 10 (5.0%) patients were diagnosed clin-
ically (negative serological test but strong clinical suspicion of
VL and aspiration contraindicated). Eighty-nine patients were
diagnosed with VL relapse (67 ﬁrst relapse, 22 second or further
episode), of whom 76 (85.4%) were conﬁrmed parasitologi-
cally by splenic aspiration, 13 (14.6%) were diagnosed clini-
cally because aspiration was contraindicated, and 79 (88.8%)
were HIV-positive.
Patients were predominantly (91%) male, with no difference in
this proportion by HIV status (Table 1)o rV Le p i s o d e( Table 2).
Two patients were pregnant (1 HIV-negative primary VL,
1 HIV-positive VL relapse); both were discharged without test
of cure (contraindicated because of pregnancy) but with good
response to treatment. HIV-positive patients were older, more
malnourished, and less anemic than HIV-negative patients
(Table 1). The prevalence of tuberculosis coinfection was
higher in HIV-positive (29.7%) than in HIV-negative (7.4%)
patients. Jaundice was more common among HIV-negative
(12.8%) than among HIV-positive (0.5%) patients. VL relapse
was more common among HIV-positive patients (40.5%) than
among HIV-negative patients (10.6%). Among HIV-positive
patients, relapse patients had larger spleens and were more
malnourished compared with primary VL patients (Table 2).
Treatment Outcomes
The total AmBisome dose received by patients who completed
treatment ranged from 25.0 mg/kg to 40.5 mg/kg (median
30.0 mg/kg). Two patients received 7 instead of 6 doses. A test-
of-cure aspirate was performed in 129 of 179 (72.1%) HIV-
positive primary VL patients and 75 of 84 (89.3%) VL relapse
patients. Reasons for not performing a test of cure included
no palpable spleen (n 5 13), nonattendance at test-of-cure
appointment (n 5 13), and splenic aspiration contraindicated
(n 5 7). Nineteen patients (6.6%) died during AmBisome
treatment.The mostcommoncausesofdeathwere sepsis(31%),
congestive heart failure (19%), and bleeding (19%).
Initial cure was 92.6% in HIV-negative patients compared
with 59.5% in HIV-positive patients (P , .001), mainly due to
parasitological failures (0% in HIV-negative vs 32.3% in HIV-
positive patients; P , .001; Table 3). There was no difference in
mortality by HIV status (6.4% in HIV-negative vs 6.7% in HIV-
positive patients; P 5 .87).
AmBisome was much less effectivein HIV-positiveVL relapse
patientsthaninHIV-positiveprimaryVLpatients,withinitialcure
rates of 38.0% versus 74.1%, respectively (P , .001) (Table 4).
Parasitological failures were 55.7% versus 16.4% (P , .001), but
there was no difference in mortality (7.8% vs 5.1%; P 5 .65).
Parasitological failures in patients with multiple relapses were
68.2% (15 of 22) versus 50.9% (29 of 57) in patients admitted
for ﬁrst relapse (P 5 .17).
The drug usedforprevioustreatmentwasknownin83.5%(66
of79)ofHIV-positive VLrelapse patients.Of these,25.8%(17 of
66 ) had previous exposure to AmBisome or amphotericin B.
Previous AmBisome or amphotericin B exposure was reported
by 14 of 44 (31.8%) HIV-positive VL relapse patients who
experienced parasitological failure versus 2 of 30 (6.7%) pa-
tients who were cured (P 5 .01). The median interval between
VL episodes in patients who received previous AmBisome treat-
ment (n 5 13) was 4 months (range, 2–8 months), signiﬁcantly
e154 d CID 2011:53 (15 December) d Ritmeijer et al
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 shorter than the median 18 months (range, 4–120 months) in
patients who had received SSG (n 5 44; P , .001).
Independent risk factors for parasitological failure in HIV-
positive VL patients were a diagnosis of relapse VL versus pri-
maryVL(odds ratio [OR]5 4.43;95% conﬁdenceinterval[CI],
1.57–12.53; P 5 .005) and larger spleen size on admission
(OR 5 1.18; 95% CI, 1.01–1.39; P5 .04; Table 5). Age, body mass
index, hemoglobin, and tuberculosis infection were not associ-
ated with parasitological failure in HIV-positive VL patients.
Rescue Treatment
Of 63 HIV-positive patients with parasitological failure after
AmBisome monotherapy, 58 (92.1%) received SSG rescue treat-
ment and 5 were retreated with AmBisome due to SSG in-
tolerance. Of the 58 patients retreated with SSG, 41 (70.7%)
were cured parasitologically, 9 (15.5%) died, 7 (12.1%) de-
faulted or were transferred, and 1 (relapse after previous SSG
treatment) failed treatment parasitologically. Of the 5 patients
retreated with AmBisome, 3 had a negative test of cure, 1 was
transferred, and 1 failed parasitologically. Rescue treatment
increased the overall cure rate in HIV-positive patients to
82.1% (160 of 195), with no difference between primary and
relapse VL patients (85.3% vs 78.5%; P 5 .25).
HIV Treatment
Of the 195 HIV-positive patients, ART status was known for
87 patients: 42 were previously on ART, 28 were initiated on
ARTafter VLadmission, and17werenot onART beforeorafter
admission. CD4
1 cell counts on admission for VL treatment
were available for 43 patients, of whom 21 (49%) had a CD4
1
count of ,100 cells/uL, and 29 (67%) ,200 cells/uL. The mean
(SD) CD4
1 count was 155 (123) cells/uL. There was no differ-
ence in mean CD4 counts between patients on ART versus those
notonART (189vs134 cells/uL; P5 .18), between patientswith
primary versus relapse VL (150 vs 159 cells/uL; P 5 .83), or
between patients with initial cure versus parasitological failure
Figure 1. Patient flow diagram.
High-Dose AmBisome for Visceral Leishmaniasis in Ethiopia d CID 2011:53 (15 December) d e155
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 (119vs183cells/uL;P5.07).Intotal,55%(12of22) ofpatients
who were on ART before admission for VL had a CD4
1 cell
count of ,200 cells/uL.
DISCUSSION
High-dose AmBisome monotherapy (30 mg/kg) was safe and
effective in severely ill HIV-negative VL patients. Treatment
outcomes (92.6% initial cure, 6.4% mortality) were similar to
those observed in 2010 in nonsevere VL treated with SSG/
paromomycin in southern Sudan (94.3% and 4.0%, respectively;
N 5 2,618)andwith SSG monotherapyin eastern Sudan (92.9%
and 3.3%, respectively; N 5 878) [MSF, unpublished data].
AmBisome was equally safe but much less effective in HIV-
positive VL patients (59.5% initial cure, 6.7% mortality) due to
the higher proportion of parasitological failures (32.3% vs 0%in
HIV-negative patients). AmBisome was even less effective in
HIV-positive VL relapses (38.0% initial cure, 55.7% parasito-
logical failure). Initial cure rates in HIV-positive VL patients
treated in Europe with similar total doses of AmBisome are
80%–100% [25–27], even though CD4
1 counts in our patients
were similar (or higher) [28, 29]. Although these 2 groups are
not directly comparable, the suggestion that L. donovani in East
Africa might be intrinsically less sensitive to amphotericin B is
supported by observations from the Sudan region [18, 30].
Our data conﬁrm that SSG is unacceptably toxic in HIV-
positive VL patients. In a previous clinical trial, we showed
that mortality during SSG treatment was 15.6% in HIV-positive
versus 2.9% in HIV-negative VL patients (and 1.6% in HIV-
positive VL patients treated with miltefosine [4]). In our study,
rescue treatment of HIV-positive patients with AmBisome
treatment failure increased the overall cure rate from 59.5% to
82.6%, but mortality in patients retreated with SSG was high
(15.5%),oftenduetoSSGtoxicity.RetreatmentwithAmBisome
ledtoparasitological curein 3of 5patients.Hence, patientswith
a signiﬁcant reduction in parasite burden (eg, $2 log grades in
splenic aspirate) could be considered slow responders who may
respond to higher dosesof AmBisome. Patients who continue to
show inadequate parasitological response should be retreated
with miltefosine or paromomycin (with SSG as a last resort),
Table 2. Characteristics of HIV-Positive Patients According to
Visceral Leishmaniasis Episode
Primary VL
(n 5 116)
Relapse VL
(n 5 79)
Median Range Median Range P value
a
Age (y) 30 18–56 30 10–56 .85
Spleen size (cm) 6 0–20 8 3–20 .006
Hb (g/dL) 7.6 2.5–13.1 7.5 2.7–11.7 .48
BMI (kg/m
2) 16.2 10.8–25.5 15.4 11.0–18.9 .04
No. % No. % P value
b
Sex (male) 105 90.5 74 93.7 .60
TB coinfection 31 26.7 27 34.2 .34
Jaundice 0 0 1 1.3 1.00
Abbreviations: BMI, body mass index; Hb, hemoglobin; HIV, human
immunodeﬁciency virus; TB, tuberculosis; VL, visceral leishmaniasis.
a Student t test (continuous variables).
b Fisher exact test (binary variables).
Table 3. Initial Treatment Outcome by HIV Status
HIV negative
(n 5 94)
HIV positive
(n 5 195)
No. % No. % P value
a
Initial cure 87 92.6 116 59.5 ,.001
Death 6 6.4 13 6.7 .87
Parasitological failure 0 0 63 32.3 .001
Default/transfer 1 1.1 3 1.5 1.00
Abbreviation: HIV, human immunodeﬁciency virus.
a Fisher exact test.
Table 1. Patient Characteristics According to HIV Status
HIV negative
(n 5 94)
HIV positive
(n 5 195)
Median Range Median Range P value
a
Age (y) 24 1.5–67 30 10–56 ,.001
Spleen size (cm) 8 0–20 8 0–20 .94
Hb (g/dL) 5.7 2.1–14.5 7.6 2.5–13.1 .001
BMI (kg/m
2) 16.2 11.0–22.2 15.9 10.8–25.5 .01
No. % No. % P value
b
Sex (male) 83 88.3 179 91.8 .46
TB coinfection 7 7.4 58 29.7 ,.001
Jaundice 12 12.8 1 ,1 ,.001
VL relapse 10 10.6 79 40.5 ,.001
Abbreviations: BMI, body mass index; Hb, hemoglobin; HIV, human immuno-
deﬁciency virus; TB, tuberculosis; VL, visceral leishmaniasis.
a Student t test comparing mean values.
b Fisher exact test.
Table 4. Initial Treatment Outcome in HIV-Positive Patients by
Visceral Leishmaniasis Episode
Primary VL
(n 5 116)
Relapse VL
(n 5 79)
No. % No. % P value
a
Initial cure 86 74.1 30 38.0 ,.001
Death 9 7.8 4 5.1 .65
Parasitological failure 19 16.4 44 55.7 ,.001
Default/transfer 2 1.7 1 1.3 1.00
Abbreviations: HIV, human immunodeﬁciency virus; VL, visceral leishmaniasis.
a Fisher exact test.
e156 d CID 2011:53 (15 December) d Ritmeijer et al
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 preferably in combination, assuming that a combination of
2 drugs with different modes of action may be more effective
than single-drug treatment.
Parasitological clearance at the end of treatment is not a cer-
tainpredictorofnofuturerelapse[11,26,29].Moreover,clinical
response does not necessarily indicate parasitological clearance
[28]. Trials of SSG in Sudan [31] and paromomycin in India
[32] showed that scanty parasites at the end of treatment in
HIV-negative patients usually clear spontaneously before the
spleen is reaspirated 1 month later. In contrast, we reported
previously that initial parasitological failure in HIV-positive VL
patients was invariably followed by further relapses and high
mortality [15]. The migrant farm laborers in our study may
have difﬁculty returning for repeat treatment, so initial para-
sitological cure is crucial.
Our ﬁnding that spleen size on admission is a risk factor for
parasitologicalfailureisconsistentwithresultsfromourstudyin
southern Sudan which showed that splenomegaly is a risk factor
for VL relapse [33]. Splenomegaly on admission may indicate
severity of illness, parasite burden, and degree of immunosup-
pression. The prevalence of triple coinfection (VL, HIV, and
tuberculosis) among HIV-positive VL patients in our study was
29.7%, similar to that observed in another Ethiopian study
[14]. However, our regression model indicated that tubercu-
losis was not an independent risk factor for parasitological
failure in HIV-positive VL patients.
Even though VL is considered an AIDS-deﬁning condition
and a valid entry point to commence ART irrespective of CD4
1
cell count, a signiﬁcant proportion of HIV-positive patients in
our study were not yet on ART. This was because many patients
in this predominantly male migrant patient population did not
meet the criteria for commencing ART (motivation to start and
adhere to lifelong ART, and/or attendance at follow-up clinics).
InEurope,ARThasreducedtheincidenceofVL[34],prolonged
intervalsbetween relapses,reducedrelapse rates[12,34–36],and
improvedsurvival[29].A study in Ethiopia demonstrated that
A R Tr e d u c e dt h er i s ko fV Lr e l a p s eb y5 0 % ,a l t h o u g ha n
impact on survival could not be demonstrated [15]. ART
does not guarantee adequate CD4
1 cell count reconstitution
in L. donovani–infected patients, because 55% (12 of 22) of
patients who had started ART before admission for VL had
a CD4
1 cell count ,200 cells/lL. It is likely that persistent
Leishmania parasites hold the patient in a state of immuno-
suppression, and the inability to regain cellular immunity leads
to recrudescence of parasites and relapse.
We may have underestimated parasitological failure rates,
despite good clinical response to treatment, because 27.9% of
HIV-positive patients and 10.7% of relapsed patients did not
haveaparasitologicaltestofcure.Ourobservationthattheonset
of VL relapse in HIV-positive patients occurred much sooner
after AmBisome treatment than after SSG treatment may have
beenbiasedbecausepatientswithpreviousSSGtreatmentwould
have been survivors from the period before the introduction of
AmBisome.
High rates of treatment failure indicate that combination
therapy, instead of AmBisome monotherapy, should be used to
treat VL in HIV-positive patients. Combinations of AmBisome
with safer drugs (eg, paromomycin, miltefosine) should be
evaluated to circumvent the toxicity of antimonials. Although
AmBisome-resistant parasites have not yet been demonstrated
in patients coinfected with HIV and Leishmania infantum after
repetitive treatment or prophylaxis [37], we are concerned that
the already suboptimal effectiveness of AmBisome could be
eroded by the emergence of drug-resistant Leishmania strains.
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Table 5. Multivariable Logistic Regression Analysis of Risk Factors for Parasitological Failure in HIV-Positive Visceral Leishmaniasis
Patients (n 5 80)
Risk factor
a No parasites (n 5 37) Parasites (n 5 43) OR (95% CI)
b P value
Age (y) 31.3 (7.3) 33.5 (7.4) 1.05 (.98–1.13) .2
BMI (kg/m
2) 16.1 (2.8) 15.5 (1.7) 0.90 (.70–1.17) .4
Hb (g/dL) 8.3 (2.0) 7.6 (1.7) 0.81 (.61–1.10) .2
Spleen size (range, 0–20) 7.5 (3.6) 9.8 (3.8) 1.18 (1.01–1.39) .04
TB (%) 35.1 37.2 0.70 (.22–2.18) .5
VL relapse (vs primary VL, %) 29.7 69.8 4.43 (1.57–12.53) .005
Abbreviations: BMI, body mass index; CI, conﬁdence interval; Hb, hemoglobin; HIV, human immunodeﬁciency virus; OR, odds ratio; TB, tuberculosis; VL, visceral
leishmaniasis.
a Mean (SD) unless otherwise indicated.
b Adjusted for all variables in table.
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